Prestarium A 10mg tablets 30

$24.50
Size chart
Women's clothing size
SizeXSSML
Euro 32/34 36 38 40
USA 0/2 4 6 8
Bust(in) 31-32 33 34 36
Bust(cm) 80.5-82.5 84.5 87 92
Waist(in) 24-25 26 27 29
Waist(cm) 62.5-64.5 66.5 69 74
Hips(in) 34-35 36 37 39
Hips(cm) 87.5-89.5 91.5 94 99
How To Measure Your Bust

With your arms relaxed at your sides, measure around the fullest part of your chest.

How To Measure Your Waist

Measure around the narrowest part of your natural waist, generally around the belly button. To ensure a comfortable fit, keep one finger between the measuring tape and your body.

Volume discounts

Quantity Unit discount You Save
2 28% $13.72
3 33% $24.26
4 40% $39.20
 Customer ratings and reviews
Nobody has posted a review yet
in this language
Reference:
Love0
Add to compare0
Add to wishlist
Description
Country
Russia
Active ingredient
Perindopril
Dosage

10 mg

Composition

Active substance: perindopril arginine 10 mg, which is respectively. 6,790 mg perindopril.
Excipients: Lactose
monohydrate, magnesium stearate, maltodextrin, silicon dioxide colloidal
hydrophobic, carboxymethyl starch sodium, glycerol, hypromellose,
macrogol 6000, titanium dioxide.

Pharmacological properties

Perindopril is an ACE inhibitor. ACE, or kininase II, is an exopeptidase that carries out both the conversion of angiotensin I into the vasoconstrictor substance angiotensin II, and the destruction of bradykinin, which has a vasodilating effect, to an inactive heptapeptide.

Inhibition of ACE leads to a decrease in the concentration of angiotensin II in plasma blood, which causes an increase in the activity of renin of blood plasma (by the mechanism of negative feedback) and a decrease in the secretion of aldosterone.

Since ACE inactivates bradykinin, the suppression of ACE is accompanied by an increase in the activity of both the circulating and tissue kallikrein-kinin system, while the prostaglandin system is also activated. It is possible that this effect is part of the mechanism of antihypertensive action of ACE inhibitors, as well as the mechanism for the development of some side effects of drugs of this class (for example, cough).

Indications for use
  • arterial hypertension;
  • chronic heart failure;
  • prevention of repeated stroke (combination therapy with indapamide) in patients who have had a stroke or transient cerebral circulation disorder of the ischemic type;
  • Stable CHD: to reduce the risk of cardio- vascular complications.
Contraindications
  • hypersensitivity to the active substance, other ACE inhibitors and excipients that make up the drug;
  • angioedema (angioedema) in the anamnesis associated with taking an ACE inhibitor;
  • hereditary / idiopathic angioedema;
  • simultaneous use with aliskiren and aliskiren-containing drugs in patients with diabetes mellitus or impaired renal function (GFR <60 ml / min / 1.73 m 2 surface area of the body);
  • pregnancy;
  • the period of breastfeeding;
  • age up to 18 years (efficacy and safety have not been established).
  • lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome;

Caution should be exercised use the drug for bilateral stenosis of the renal arteries or the presence of only one functioning kidney; renal failure; systemic connective tissue diseases (including systemic lupus erythematosus, scleroderma); therapy with immunosuppressants, allopurinol, procainamide (risk of neutropenia, agranulocytosis); reduced BCC (taking diuretics, salt-free diet, vomiting, diarrhea); angina pectoris; cerebrovascular diseases; renovascular hypertension; diabetes mellitus; chronic heart failure IV FC according to the NYHA classification; simultaneous use of potassium-sparing diuretics, potassium preparations, potassium-containing substitutes for edible salt, lithium preparations; hyperkalemia; surgery/general anesthesia; hemodialysis using high-flow membranes; desensitizing therapy; LDL apheresis; condition after kidney transplantation; aortic stenosis / mitral stenosis / hypertrophic obstructive cardiomyopathy; in patients of the Negroid race.

Dosage and Administration

The drug is prescribed inside 1 time / day in the morning, before meals.

Overdose

Data on drug overdose are limited.

Symptoms: a pronounced decrease in blood pressure, shock, disturbances in the water-electrolyte balance, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, cough.

Treatment: with a pronounced decrease in blood pressure, the patient should be transferred to a supine position with raised legs; if necessary, a 0.9% solution of sodium chloride, a solution of catecholamines should be introduced intravenously. Perindoprilate, the active metabolite of perindopril, can be removed from the body by dialysis. With the development of bradycardia resistant to therapy, it may be necessary to install an artificial pacemaker. It is necessary to constantly monitor the indicators of the basic vital functions of the body, the concentration of creatinine and electrolytes in the blood serum.

Side effects

The safety profile of perindopril is consistent with the safety profile of ACE inhibitors.

The most frequent adverse events reported in clinical studies and observed with the use of perindopril are: dizziness, headache, paresthesia, vertigo, visual impairment, tinnitus, excessive decrease in blood pressure, cough, shortness of breath, abdominal pain, constipation, diarrhea, taste disturbance, dyspepsia, nausea, vomiting, skin itching, skin rash, muscle spasms and asthenia.

Determination of the frequency of adverse reactions (in accordance with WHO recommendations) that were noted during clinical trials and / or post-registration use of perindopril: very often (≥1/10); often (≥1/100, <1/10); infrequently (≥1/1000, <1/100); rarely (≥1/10,000, <1/1000); very rarely (<1/10,000); unspecified frequency (frequency cannot be calculated by available data).

From the blood and lymphatic system: infrequently* - eosinophilia; very rarely - a decrease in hemoglobin and hematocrit, thrombocytopenia, leukopenia / neutropenia, agranulocytosis, pancytopenia, hemolytic anemia in patients with congenital deficiency of glucose-6-phosphate dehydrogenase.

From the side of metabolism: infrequently* - hypoglycemia, hyperkalemia, reversible after discontinuation of the drug, hyponatremia.

From the side of the central nervous system: often - paresthesia, headache, dizziness, vertigo; infrequently - sleep disorders, mood lability, drowsiness*, fainting*; very rarely - confusion.

From the senses: often - visual impairment, tinnitus.

From the cardiovascular system: often - excessive decrease in blood pressure and related symptoms; infrequently* - vasculitis, tachycardia, palpitations; very rarely - heart rhythm disturbances, angina pectoris, myocardial infarction and stroke, possibly due to excessive decrease in blood pressure in patients from the high-risk group.

From the respiratory system: often - cough, shortness of breath; infrequently - bronchospasm; very rarely - eosinophilic pneumonia, rhinitis.

From the digestive system: often - constipation, nausea, vomiting, abdominal pain, impaired taste, dyspepsia, diarrhea; infrequently - dryness of the oral mucosa; very rarely - pancreatitis.

From the liver and biliary tract: very rarely - hepatitis (cholestatic or cytolytic).

From the skin and subcutaneous fat: often - skin itching, rash; infrequently* - photosensitivity, pemphigus, increased sweating; very rarely - erythema multiforme.

Allergic reactions: infrequently - angioedema of the face, lips, upper and lower extremities, mucous membranes, tongue, vocal folds and / or larynx, urticaria.

From the musculoskeletal system: often - muscle spasms; infrequently* - arthralgia, myalgia.

From the kidneys and urinary tract: infrequently - renal failure; very rarely - acute renal failure.

From the reproductive system: infrequently - erectile dysfunction.

General disorders and symptoms: often - asthenia; infrequently - chest pain*, peripheral edema*, weakness*, fever*, falls*.

On the part of laboratory indicators: rarely - an increase in the activity of hepatic transaminases and bilirubin in the blood serum; infrequently* - an increase in the concentration of urea and creatinine in the blood plasma.

*The frequency of adverse reactions identified by spontaneous reports is estimated on the basis of data from clinical trial results.

Adverse events noted in clinical trials

In the EUROPA study, only serious adverse events were reported. Serious adverse events were were noted in 16 (0.3%) patients in the perindopril group and in 12 (0.2%) patients in the placebo group. In the group of perindopril in 6 patients there was a pronounced decrease in blood pressure, in 3 patients - angioedema, in 1 patient - sudden cardiac arrest. The frequency of withdrawal of the drug due to cough, a pronounced decrease in blood pressure or other cases of intolerance was higher in the perindopril group compared with the placebo group.

Storage conditions

The drug should be stored out of the reach of children. Special conditions for storage of the drug are not required.
Shelf life - 3 years

Read more
Product Details

Data sheet

Brand
None
service_future
otc_05
Dosage form
Tablets
Dosage
10 mg
INN
Perindopril
Number of tablets
30
INN Russian
None
Russian title
Престариум А
Reviews
No comments
 Reviews

Be the first to write your review !

Menu

Settings

Create a free account to save loved items.

Sign in

Create a free account to use wishlists.

Sign in